Business Context and Reporting Period
This Form 8-K Current Report was filed by OptimizeRx Corporation (OPRX) on March 10, 2025. The filing reports a significant management change effective as of the report date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Stephen Silvestro as Chief Executive Officer (CEO), effective March 10, 2025. Mr. Silvestro previously served as the Company's President and Interim CEO. In connection with this appointment, the Company entered into an Amended and Restated Employment Offer Letter with the following compensation terms:
- Base Salary: $500,000 annually.
- Target Bonus: 80% of the annual base salary.
- Equity Grant: A one-time grant valued at $1.0 million on the grant date.
- Other Benefits: Eligibility for the annual equity grant program, Executive Severance Plan, and standard employee benefit programs.
Guidance, Outlook, and Risks
The filing includes a press release regarding the management changes but does not provide specific financial guidance, forward-looking outlook, or new risk factors. The document notes that the press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Employment Letter (Exhibit 10.1) for specific vesting schedules and severance conditions.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.
- Confirm the impact of the $1.0 million equity grant on the company's capital structure and dilution.
- Check subsequent filings for any changes to the interim CEO status or board composition.